エピジェネティクス市場の評価：後成的変化タイプ・製品&サービス・用途・エンドユーザー・地域別の機会および予測 (2017-2031年)

世界のエピジェネティクスの市場規模は、2023年の15億4,000万米ドルから、2024年から2031年の予測期間中は14.73%のCAGRで推移し、2031年には46億1,000万米ドルの規模に成長すると予測されています。

世界のエピジェネティクス市場を形成する要因はさまざまであり、外部刺激への曝露、遺伝子検査に対する意識の高まり、研究への注力の高まり、疾患の早期発見のためのエピジェネティクスの利用、バイオテクノロジー企業の資金調達、AIベースのソフトウェアの人気の高まり、癌治療のためのエピジェネティクスの利用の高まりなどが挙げられます。

世界のエピジェネティクス市場の主要企業は、エピジェネティクス産業の進歩を促進するため、特に高所得国においてR&Dに多額の投資を行っています。農薬や重金属のような有害な化学物質への一般市民の暴露の増加は、DNAとその修復プロセスを改ざんし、遺伝子の突然変異や病気につながることによって、彼らの健康と幸福に重大な脅威をもたらしています。疾患の増加は、エピジェネティック検査アッセイとキットの必要性を押し上げ、世界のエピジェネティクス市場の拡大をさらに促進しています。

AIにはエピジェネティクスで得られたデータの文書化、解明、予測を行う能力があります。AIベースのソフトウェアの使用は、この分野の研究手法を変革し、世界のエピジェネティクス市場の革新と開発を後押しする結果となっています。悪性で治療不可能な癌に苦しむ患者において、エピジェネティクスは癌で起こる遺伝子異常を逆転させるのに役立つ重要な代替治療となっています。エピジェネティクスの応用は、テーラーメイド医薬品の形成や慢性疾患の早期発見など、癌以外にも広がっており、世界のエピジェネティクス市場の大きな成長につながっています。

当レポートでは、世界のエピジェネティクスの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 エピジェネティクス市場の展望

• 市場規模・予測
• 後成的変化タイプ別
  • DNAメチル化
  • ヒストン修飾
  • その他
• 製品・サービス別
  • 酵素
  • キット・試薬
  • 機器・付属品
  • ソフトウェア
  • サービス
• 用途別
  • 腫瘍
  • 心臓血管
  • 免疫
  • 代謝
  • その他
• エンドユーザー別
  • 病院・診療所
  • バイオテクノロジーおよび製薬企業
  • 学術研究機関
  • その他
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ
• 企業別市場シェア

第5章 エピジェネティクス市場の展望：地域別

• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第6章 市場マッピング

• 後成的変化タイプ別
• 製品・サービス別
• 用途別
• エンドユーザー別
• 地域別

第7章 マクロ環境と産業構造

• 需給分析
• 輸出入分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長促進要因
• 成長抑制要因 (課題・障壁)

第9章 規制の枠組みとイノベーション

• 特許情勢
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析（参入5社）
• 特許分析（該当する場合）

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の展望

• Illumina, Inc.
• Abbott Laboratories
• Eli Lilly & Company
• GlaxoSmithKline Plc.
• Johnson & Johnson
• Merck & Co. Inc.
• Mylan NV.
• Novartis AG
• Pfizer, Inc.
• Bayer AG

第14章 戦略的提言

第15章 お問い合わせ・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1.Global Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 2.Global Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 3.Global Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 4.Global Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 5.Global Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 6.Global Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 7.Global Epigenetics Market Share (%), By Region, 2017-2031F
• Figure 8.North America Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 9.North America Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 10.North America Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 11.North America Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 12.North America Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 13.North America Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 14.North America Epigenetics Market Share (%), By Country, 2017-2031F
• Figure 15.United States Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 16.United States Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 17.United States Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 18.United States Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 19.United States Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 20.United States Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 21.Canada Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 22.Canada Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 23.Canada Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 24.Canada Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 25.Canada Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 26.Canada Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 27.Mexico Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 28.Mexico Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 29.Mexico Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 30.Mexico Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 31.Mexico Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 32.Mexico Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 33.Europe Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 34.Europe Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 35.Europe Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 36.Europe Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 37.Europe Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 38.Europe Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 39.Europe Epigenetics Market Share (%), By Country, 2017-2031F
• Figure 40.Germany Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 41.Germany Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 42.Germany Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 43.Germany Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 44.Germany Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 45.Germany Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 46.France Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 47.France Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 48.France Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 49.France Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 50.France Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 51.France Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 52.Italy Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 53.Italy Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 54.Italy Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 55.Italy Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 56.Italy Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 57.Italy Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 58.United Kingdom Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 59.United Kingdom Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 60.United Kingdom Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 61.United Kingdom Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 62.United Kingdom Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 63.United Kingdom Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 64.Russia Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 65.Russia Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 66.Russia Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 67.Russia Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 68.Russia Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 69.Russia Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 70.Netherlands Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 71.Netherlands Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 72.Netherlands Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 73.Netherlands Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 74.Netherlands Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 75.Netherlands Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 76.Spain Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 77.Spain Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 78.Spain Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 79.Spain Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 80.Spain Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 81.Spain Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 82.Turkey Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 83.Turkey Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 84.Turkey Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 85.Turkey Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 86.Turkey Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 87.Turkey Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 88.Poland Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 89.Poland Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 90.Poland Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 91.Poland Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 92.Poland Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 93.Poland Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 94.South America Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 95.South America Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 96.South America Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 97.South America Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 98.South America Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 99.South America Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 100.South America Epigenetics Market Share (%), By Country, 2017-2031F
• Figure 101.Brazil Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 102.Brazil Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 103.Brazil Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 104.Brazil Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 105.Brazil Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 106.Brazil Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 107.Argentina Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 108.Argentina Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 109.Argentina Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 110.Argentina Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 111.Argentina Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 112.Argentina Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 113.Asia-Pacific Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 114.Asia-Pacific Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 115.Asia-Pacific Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 116.Asia-Pacific Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 117.Asia-Pacific Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 118.Asia-Pacific Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 119.Asia-Pacific Epigenetics Market Share (%), By Country, 2017-2031F
• Figure 120.India Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 121.India Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 122.India Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 123.India Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 124.India Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 125.India Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 126.China Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 127.China Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 128.China Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 129.China Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 130.China Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 131.China Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 132.Japan Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 133.Japan Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 134.Japan Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 135.Japan Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 136.Japan Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 137.Japan Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 138.Australia Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 139.Australia Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 140.Australia Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 141.Australia Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 142.Australia Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 143.Australia Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 144.Vietnam Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 145.Vietnam Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 146.Vietnam Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 147.Vietnam Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 148.Vietnam Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 149.Vietnam Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 150.South Korea Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 151.South Korea Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 152.South Korea Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 153.South Korea Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 154.South Korea Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 155.South Korea Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 156.Indonesia Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 157.Indonesia Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 158.Indonesia Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 159.Indonesia Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 160.Indonesia Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 161.Indonesia Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 162.Philippines Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 163.Philippines Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 164.Philippines Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 165.Philippines Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 166.Philippines Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 167.Philippines Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 168.Middle East & Africa Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 169.Middle East & Africa Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 170.Middle East & Africa Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 171.Middle East & Africa Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 172.Middle East & Africa Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 173.Middle East & Africa Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 174.Middle East & Africa Epigenetics Market Share (%), By Country, 2017-2031F
• Figure 175.Saudi Arabia Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 176.Saudi Arabia Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 177.Saudi Arabia Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 178.Saudi Arabia Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 179.Saudi Arabia Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 180.Saudi Arabia Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 181.UAE Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 182.UAE Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 183.UAE Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 184.UAE Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 185.UAE Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 186.UAE Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 187.South Africa Epigenetics Market, By Value, In USD Billion, 2017-2031F
• Figure 188.South Africa Epigenetics Market, By Volume, In Thousand Units, 2017-2031F
• Figure 189.South Africa Epigenetics Market Share (%), By Type of Epigenetic Changes, 2017-2031F
• Figure 190.South Africa Epigenetics Market Share (%), By Product and Service, 2017-2031F
• Figure 191.South Africa Epigenetics Market Share (%), By Application, 2017-2031F
• Figure 192.South Africa Epigenetics Market Share (%), By End-user, 2017-2031F
• Figure 193.By Type of Epigenetic Changes Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 194.By Product and Service Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 195.By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 196.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

The global epigenetics market is projected to witness a CAGR of 14.73% during the forecast period 2024-2031F, growing from USD 1.54 billion in 2023 to USD 4.61 billion in 2031F. Various factors shape the global epigenetics market, these include exposure to external stimuli, heightened awareness of genetic testing, increased focus on research, the use of epigenetics for early disease detection, biotechnology companies raising funds, the growing popularity of AI-based software, and the growing use of epigenetics for the treatment of cancer.

Major companies in the global epigenetics market are heavily investing in research and development, especially in high-income countries, to promote advancements in the epigenetics industry. The increased exposure of the public to harmful chemicals, such as pesticides and heavy metals, poses a significant threat to their health and well-being by tampering with the DNA and its repair process, leading to mutation in the genes and illnesses. The increased number of illnesses has boosted the need for epigenetic testing assays and kits, further propelling the expansion of the global epigenetics market.

Artificial intelligence is capable of documentation, elucidation, and forecasting of data obtained in the epigenetics sector. The use of AI-based software has transformed the research methods in the field and resulted in boosting innovation and development in the global epigenetics market. In patients suffering from malignant and untreatable cancer, epigenetics has become an important treatment alternative that helps in reversing genetic aberrations that occur in cancer. Applications of epigenetics expand beyond cancer, such as the formation of tailored medicines and early detection of chronic diseases, which, in turn, have led to significant growth in the global epigenetics market.

For example, in January 2024, a genomic medicine startup, Moonwalk Biosciences announced that the company had raised a fund of USD 57 million through Series A fundraising. Through the funding, the company aims to move the products in the epigenetic pipeline and development of epigenetic engineering technology and profiling platform.

Increased Focus on Research

Major companies in the epigenetics industry are investing heavily in research activities to foster innovation, thereby boosting the growth of the global epigenetics market. The potential of epigenetics for discovering new treatment options for diseases, especially diseases short of effective therapies, has garnered attention of the investors. Also, an increased number of research activities has led to the development of new and advanced products that can be used in the treatment of cancer and other chronic diseases. These medications target blood biomarkers in cancer cells, thus representing one of the key factors contributing to the global epigenetics market growth.

For instance, the National Institute of Health (NIH) awarded a grant of USD 374,000 for three years for research focused on epigenetics in June 2022. In this research, the epigenetic changes occurring in many generations of a roundworm are being studied to shed light on epigenetic inheritance for disease and health.

Use in Early Disease Detection

Epigenetics is extremely useful in the early detection of diseases since the underlying causes of a disease can be very well understood by the insights proposed by epigenetics, which give out various reasons for mutations in gene expression that are a result of factors other than changes in the DNA sequence. Epigenetic study aids in decrypting the alterations caused by the epigenetic factors in cell specialization, gene expression, and tissue development processes to help understand the nature of the disease. It is a highly useful method of treatment for a wide range of diseases, including cancer, neurological, and cardiovascular disorders.

For instance, in January 2024, Barts Health NHS Trust and Queen Mary University of London announced their aim to investigate the early signs of disease using AI technologies through a £3 million (USD 3.78 million) partnership. The companies will focus on exploring the capacity of blood markers on DNA.

Growing Popularity of AI-Based Software

Gene is a storehouse of complex information and is responsible for the synthesis of many RNA transcripts and proteins. AI-based epigenetic software can easily manage the data stored in the gene because of its ability to analyze composite epigenetic data with precision and efficiency. The software can easily detect any abnormalities in data and predict the outcome of the disease, boosting the demand for AI-based software in the global epigenetics market. By combining multiomics data, AI can be used in combination with epigenetic information to provide customized solutions that fit each patient's unique genetic profile. The growing popularity of AI-based software will drive the growth of the global epigenetics market.

For example, FoxO Technologies Inc., an epigenetic biomarker company, announced its partnership with KR8,ai Inc. in January 2024 to secure the license for VITHAR AI Health Coach, KR8's AI-based software that provides epigenetic wellness solutions.

Increased Product Usage for Treating Cancer

Epigenetics is increasingly being used in the treatment of cancer, which is bolstering the growth of the global epigenetics market. Several factors are responsible for the growing preference for epigenetics to cure cancer. Firstly, epigenetic drugs are desirable in the personalized cancer treatment of patients who are resistant to certain drugs because of their ability to reverse drug resistance and can also be used in combination with other therapies. Secondly, unlike irreversible genetic mutations, epigenetic changes are reversible, opening new therapeutic options. Lastly, epigenetic mutations can also be used to stimulate the immunological response of the host boosting antitumoral effects.

For example, in June 2023, the clinical-stage biotechnology company Zenith Epigenetics Ltd. announced progress in the development of ZEN-3694, a BET inhibitor intended for the treatment of NUT Carcinoma.

North America Dominating the Market

North American countries endure a large geriatric population making a large section of the population prone to chronic diseases which greatly affects the healthcare system posing a huge burden on the economy. It is estimated that by 2040, one in five Americans will be 65 years of age or older. Around 23.5% of older Americans reported having fair or poor health in 2022, whereas the percentage of obese people varies from 32% to 46%, which fuels the need for development of innovative solutions. North America has a robust healthcare system housing one of the largest biotechnology companies in the world. The governments support the local companies by helping them launch and improve their products and invest in research and development initiatives. All these factors are responsible for the dominance of North America in the global epigenetics market.

For example, Cardio Diagnostics, Inc., a cardiovascular medicine diagnostic company announced a collaboration with Mana Capital Acquisition Corp, a cardiovascular testing company in May 2022. The corporation aimed to capture a $51 billion epigenetics market share in the US with this partnership.

Future Market Scenario (2024 - 2031F)

The global epigenetics market will be driven by the development of epigenetic editing tools such as CRISPR-based technologies.

Increased impact of deteriorating environmental conditions in developing countries will increase the disease susceptibility boosting the growth of the global epigenetics market.

Increased investigations in transgenerational epigenetic inheritance can create the desired opportunities for the global epigenetics market.

Integration of epigenetics with proteomics, genomics and transcriptomics will bolster the growth of the global epigenetics market.

Key Players Landscape and Outlook

Major companies in the global epigenetics market are opting for collaborations to grow in the marketplace. Collaborations foster innovation, creativity, and knowledge exchange. By working together, companies can easily overcome challenges and increase their chances of success in the fiercely competitive industry. It helps in improving their reputation and provides more funding opportunities to speed up the research and development efforts. Market leaders are collaborating to automate the epigenetics sector which improves the efficiency of the procedure and increases the outcomes.

For example, Bayer's Consumer Health division formed a partnership with Hurdle, a diagnostic testing company in November 2023 to develop breakthrough technologies in the field of healthy aging. With the help of Hurdle's AI-powered multi-omics the partnership aims to measure biological age using epigenetic biomarkers.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Epigenetics Market Outlook, 2017-2031F

• 4.1.Market Size & Forecast
  • 4.1.1.By Value
  • 4.1.2.By Volume
• 4.2.By Type of Epigenetic Changes
  • 4.2.1.DNA Methylation
  • 4.2.2.Histone Modification
  • 4.2.3.Others
• 4.3.By Product and Service
  • 4.3.1.Enzymes
    • 4.3.1.1.Acetyltransferases
    • 4.3.1.2.Histone Deacetylases
    • 4.3.1.3.Methyltransferases
    • 4.3.1.4.Others
  • 4.3.2.Kits and Reagents
    • 4.3.2.1.Whole Genome Amplification Kits
    • 4.3.2.2.Bisulfite Conversion Kits
    • 4.3.2.3.Antibodies
    • 4.3.2.4.Others
  • 4.3.3.Instruments and Accessories
  • 4.3.4.Software
  • 4.3.5.Service
• 4.4.By Application
  • 4.4.1.Oncology
  • 4.4.2.Cardiovascular
  • 4.4.3.Immunology
  • 4.4.4.Metabolic
  • 4.4.5.Others
• 4.5.By End-user
  • 4.5.1.Hospitals and Clinics
  • 4.5.2.Biotechnology and Pharmaceutical Companies
  • 4.5.3.Academic and Research Institutes
  • 4.5.4.Others
• 4.6.By Region
  • 4.6.1.North America
  • 4.6.2.Europe
  • 4.6.3.Asia-Pacific
  • 4.6.4.South America
  • 4.6.5.Middle East and Africa
• 4.7.By Company Market Share (%), 2023

5.Global Epigenetics Market Outlook, By Region, 2017-2031F

• 5.1.North America*
  • 5.1.1.Market Size & Forecast
    • 5.1.1.1.By Value
    • 5.1.1.2.By Volume
  • 5.1.2.By Types of Epigenetic Changes
    • 5.1.2.1.DNA Methylation
    • 5.1.2.2.Histone Modification
    • 5.1.2.3.Others
  • 5.1.3.By Product and Service
    • 5.1.3.1.Enzymes
    • 5.1.3.1.1.Acetyltransferases
    • 5.1.3.1.2.Histone Deacetylases
    • 5.1.3.1.3.Methyltransferases
    • 5.1.3.1.4.Others
    • 5.1.3.2.Kits and Reagents
    • 5.1.3.2.1.Whole Genome Amplification Kits
    • 5.1.3.2.2.Bisulfite Conversion Kits
    • 5.1.3.2.3.Antibodies
    • 5.1.3.2.4.Others
    • 5.1.3.3.Instruments and Accessories
    • 5.1.3.4.Software
    • 5.1.3.5.Service
  • 5.1.4.By Application
    • 5.1.4.1.Oncology
    • 5.1.4.2.Cardiovascular
    • 5.1.4.3.Immunology
    • 5.1.4.4.Metabolic
    • 5.1.4.5.Others
  • 5.1.5.By End-user
    • 5.1.5.1.Hospitals and Clinics
    • 5.1.5.2.Biotechnology and Pharmaceutical Companies
    • 5.1.5.3.Academic and Research Institutes
    • 5.1.5.4.Others
  • 5.1.6.United States*
    • 5.1.6.1.Market Size & Forecast
    • 5.1.6.1.1.By Value
    • 5.1.6.1.2.By Volume
    • 5.1.6.2.By Types of Epigenetic Changes
    • 5.1.6.2.1.DNA Methylation
    • 5.1.6.2.2.Histone Modification
    • 5.1.6.2.3.Others
    • 5.1.6.3.By Product and Service
    • 5.1.6.3.1.Enzymes
    • 5.1.6.3.1.1.Acetyltransferases
    • 5.1.6.3.1.2.Histone Deacetylases
    • 5.1.6.3.1.3.Methyltransferases
    • 5.1.6.3.1.4.Others
    • 5.1.6.3.2.Kits and Reagents
    • 5.1.6.3.2.1.Whole Genome Amplification Kits
    • 5.1.6.3.2.2.Bisulfite Conversion Kits
    • 5.1.6.3.2.3.Antibodies
    • 5.1.6.3.2.4.Others
    • 5.1.6.3.3.Instruments and Accessories
    • 5.1.6.3.4.Software
    • 5.1.6.3.5.Service
    • 5.1.6.4.By Application
    • 5.1.6.4.1.Oncology
    • 5.1.6.4.2.Cardiovascular
    • 5.1.6.4.3.Immunology
    • 5.1.6.4.4.Metabolic
    • 5.1.6.4.5.Others
    • 5.1.6.5.By End-user
    • 5.1.6.5.1.Hospitals and Clinics
    • 5.1.6.5.2.Biotechnology and Pharmaceutical Companies
    • 5.1.6.5.3.Academic and Research Institutes
    • 5.1.6.5.4.Others
  • 5.1.7.Canada
  • 5.1.8.Mexico

All segments will be provided for all regions and countries covered

• 5.2.Europe
  • 5.2.1.Germany
  • 5.2.2.France
  • 5.2.3.Italy
  • 5.2.4.United Kingdom
  • 5.2.5.Russia
  • 5.2.6.Netherlands
  • 5.2.7.Spain
  • 5.2.8.Turkey
  • 5.2.9.Poland
• 5.3.Asia-Pacific
  • 5.3.1.India
  • 5.3.2.China
  • 5.3.3.Japan
  • 5.3.4.Australia
  • 5.3.5.Vietnam
  • 5.3.6.South Korea
  • 5.3.7.Indonesia
  • 5.3.8.Philippines
• 5.4.South America
  • 5.4.1.Brazil
  • 5.4.2.Argentina
• 5.5.Middle East & Africa
  • 5.5.1.Saudi Arabia
  • 5.5.2.UAE
  • 5.5.3.South Africa

6.Market Mapping, 2023

• 6.1.By Types of Epigenetic Changes
• 6.2.By Product and Service
• 6.3.By Application
• 6.4.By End-user
• 6.5.By Region

7.Macro Environment and Industry Structure

• 7.1.Demand Supply Analysis
• 7.2.Import Export Analysis
• 7.3.Value Chain Analysis
• 7.4.PESTEL Analysis
  • 7.4.1.Political Factors
  • 7.4.2.Economic System
  • 7.4.3.Social Implications
  • 7.4.4.Technological Advancements
  • 7.4.5.Environmental Impacts
  • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5.Porter's Five Forces Analysis
  • 7.5.1.Supplier Power
  • 7.5.2.Buyer Power
  • 7.5.3.Substitution Threat
  • 7.5.4.Threat from New Entrant
  • 7.5.5.Competitive Rivalry

8.Market Dynamics

• 8.1.Growth Drivers
• 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

• 9.1.Patent Landscape
• 9.2.Innovations/Emerging Technologies

10.Key Players Landscape

• 10.1.Competition Matrix of Top Five Market Leaders
• 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4.SWOT Analysis (For Five Market Players)
• 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

• 13.1.Illumina, Inc.
  • 13.1.1.Company Details
  • 13.1.2.Key Management Personnel
  • 13.1.3.Products & Services
  • 13.1.4.Financials (As reported)
  • 13.1.5.Key Market Focus & Geographical Presence
  • 13.1.6.Recent Developments
• 13.2.Abbott Laboratories
• 13.3.Eli Lilly & Company
• 13.4.GlaxoSmithKline Plc.
• 13.5.Johnson & Johnson
• 13.6.Merck & Co. Inc.
• 13.7.Mylan NV.
• 13.8.Novartis AG
• 13.9.Pfizer, Inc.
• 13.10.Bayer AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer